文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

骨寡转移性前列腺癌转移灶导向治疗的疗效分析

Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
PubMed 文献 · Radiat Oncol · 2021-06-30

该回顾性研究评估了80例骨寡转移前列腺癌患者(115处病灶)接受转移灶导向放疗(MDT)的结局,按ESTRO/EORTC寡转移分类进行分析。中位随访23个月,中位生化无进展生存期(bPFS)为16.5个月,临床无进展生存期(cPFS)为21.5个月,2年局部控制率达98.3%,未发生≥3级毒性。

要点

  • 骨寡转移前列腺癌患者接受MDT后2年局部控制率达98.3%,安全性良好。
  • 中位bPFS为16.5个月,中位cPFS为21.5个月,2年后超过2/5患者无进展。
  • 年龄≤70岁和同期ADT与cPFS显著相关,寡转移分类和激素敏感性在单变量中预测cPFS。

核心结论

  • MDT对前列腺癌骨寡转移安全且局部控制率高,2年后超过2/5患者无进展。

研究设计与样本

  • 回顾性评估2011至2019年80例连续寡转移前列腺癌患者(115处骨病灶)接受MDT的临床数据。
  • 纳入激素敏感(77.5%)和去势抵抗(22.5%)患者,MDT采用常规分割或立体定向体部放疗(SBRT)技术。

主要发现

  • MDT时31%患者为原发同步寡转移,46%为原发治疗后异时寡复发,23%为原发寡进展、重复寡转移或诱导寡转移。
  • 中位BED3为93.3 Gy(范围75.8-95.3 Gy),69%患者接受同期ADT。
  • 中位随访23个月,中位bPFS和cPFS分别为16.5和21.5个月,2年局部控制率为98.3%。
  • 多变量分析中年龄≤70(HR=2.60,95%CI 1.20-5.62,p=0.015)和同期ADT(HR=0.26,95%CI 0.12-0.58,p=0.001)与cPFS显著相关。

关键数值与推荐

  • 中位BED3为93.3 Gy(范围75.8-95.3 Gy)。
  • 2年局部控制率为98.3%。
  • 中位bPFS为16.5个月,中位cPFS为21.5个月。
  • 年龄≤70岁HR=2.60(95%CI 1.20-5.62,p=0.015),同期ADT HR=0.26(95%CI 0.12-0.58,p=0.001)。

临床怎么用

  • 对骨寡转移前列腺癌患者,MDT可提供高局部控制率且≥3级毒性未见,支持其在该人群中的应用。
  • 同期ADT与改善的cPFS相关,年龄≤70岁与cPFS相关,可辅助临床决策。

局限性

  • 回顾性研究,样本量80例,随访中位23个月。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this work was to investigate the outcome of metastasis-directed radiotherapy (MDT) in prostate cancer patients with bone metastases following current ESTRO/EORTC subclassifications for oligometastatic disease. METHODS: Clinical data of 80 consecutive oligometastatic patients with 115 bone lesions receiving MDT between 2011 and 2019 were retrospectively evaluated. Hormone-sensitive (77.5%) and castrate-resistant (22.5%) patients were included. MDT was delivered with conventional fractionated or stereotactic body radiotherapy (SBRT) techniques. Kaplan-Meier method, log rank test, as well as Cox regression were used to calculate local control (LC) and biochemical and clinical progression-free survival (bPFS/cPFS). RESULTS: At the time of MDT 31% of patients had de-novo synchronous oligometastatic disease, 46% had de-novo metachronous oligorecurrence after primary treatment and 23% had either de-novo oligoprogressive disease, repeat oligometastatic disease or induced oligometastatic disease. The median BED3 was 93.3 Gy (range 75.8-95.3 Gy). Concomitant ADT was administered in 69% of patients. After a median follow-up of 23 months the median bPFS and cPFS were 16.5 and 21.5 months, respectively. The 2-year LC rate was 98.3%. In multivariate analysis, age ≤ 70 (HR = 2.60, 95% CI 1.20-5.62, p = 0.015) and concomitant ADT (HR = 0.26, 95% CI 0.12-0.58, p = 0.001) significantly correlated with cPFS. Category of oligometastatic disease and hormone-sensitivity were predictive for cPFS in univariate analysis. Of 45 patients with biochemical relapse, nineteen patients (42.2%) had repeat oligometastatic disease. Fourteen patients (31%) underwent a second course of MDT. No patients experienced grade ≥ 3 toxicities. CONCLUSIONS: MDT is safe and offers high local control rates in bone oligometastases of prostate cancer. At 2 years after treatment, more than 2 out of 5 patients are progression-free. Trial registration Retrospectively registered.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Rogowski P, Trapp C, von Bestenbostel R, et al. Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiat Oncol. 2021. PMID: 34193194. doi:10.1186/s13014-021-01849-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。